Temporary elimination of IL-10 enhanced the effectiveness of cyclophosphamide and BMDC-based therapy by decrease of the suppressor activity of MDSCs and activation of antitumour immune response

Rossowska, Joanna; Anger, Natalia; Kicielińska, Jagoda; Pajtasz‐Piasecka, Elżbieta; Bielawska‐Pohl, Aleksandra; Wojas-Turek, Justyna; Duś, Danuta

doi:10.1016/j.imbio.2014.10.009

Cited by 23 publications

(26 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The activation of immune suppressor mechanisms often appears in cancer patients with chemotherapy [66]. Temporary elimination of IL-10 could overcome the immunosuppressive tumour barrier in mice [67]. The therapeutical potential of the PD-1 and PD-L1 pathway, which is important for T cell regulation in a variety of infectious, autoimmune, and cancer models in mice, was also maximised in recent years.…”

Section: Discussionmentioning

confidence: 99%

Immunoregulation of Shenqi Fuzheng Injection Combined with Chemotherapy in Cancer Patients: A Systematic Review and Meta‐Analysis

Yang

Wang

Xiao

et al. 2017

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Background. Immunosuppression is a well-recognised complication of chemotherapy in cancer patients. We assemble the clinical evidence that SQI, an adjuvant drug for lung cancer and gastric cancer which was widely prescribed in China, interventions could increase objective tumour response and regulate immunity in cancer patients undergoing chemotherapy. Methods. We undertook a systemic review of the clinical data from randomised controlled trials up to September 2015 in which a SQI intervention was compared with a control arm in patients undergoing conventional chemotherapy. Revman 5.0 Software was used for the data analysis. Results. 49 randomised controlled trials were included in the systematic review. The meta-analysis results demonstrated that the SQI intervention with conventional chemotherapy exhibited better therapeutic efficacy than the conventional chemotherapy group with a statistically significant higher objective tumour response. Cotreatment with SQI could enhance NK, CD3 +, CD4 + level, and CD4 +/CD8 + ratio comparing with the conventional chemotherapy group. Conclusions. The conclusions of this review might suggest a high risk of bias due to the low quality and the limitation of cancer types in the included trials. A more reliable conclusion regarding the immunoregulation of SQI could be reached based on more trials of higher quality.

show abstract

Section: Discussionmentioning

confidence: 99%

Immunoregulation of Shenqi Fuzheng Injection Combined with Chemotherapy in Cancer Patients: A Systematic Review and Meta‐Analysis

Yang

Wang

Xiao

et al. 2017

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“…Secondly, they generate a large amount of oxygen free radicals that can cause conformational alteration or the disruption of membrane receptors of killing immune cells, leading to ineffective identification of tumor antigens (conformational alteration or disruption of TCR), ineffective activation (conformational alteration or disruption of IL-2R), and/or hindered migration (conformational alteration or disruption of CCR2) [78,79]. Thirdly, they secrete negative immuneregulatory factors, such as IL-10, and TGF-beta, to inhibit the activity or migratory ability of killing immune cells [80,81].…”

Section: Anti-tumor Strategy Via Targeting Immunosuppressive Mdsc Andmentioning

confidence: 99%

Novel Therapeutic Strategies for Solid Tumor Based on Body’s Intrinsic Antitumor Immune System

Duan

2018

Cell Physiol Biochem

View full text Add to dashboard Cite

The accumulation of mutated somatic cells due to the incompetency of body’s immune system may lead to tumor onset. Therefore, enhancing the ability of the system to eliminate such cells should be the core of tumor therapy. The intrinsic antitumor immunity is triggered by tumor-specific antigens (TSA) or TSA-sensitized dendritic cells (DC). Once initiated, specific anti-tumor antibodies are produced and tumor-specific killer immune cells, including cytotoxic T lymphocytes (CTL), NK cells, and macrophages, are raised or induced. Several strategies may enhance antitumor action of immune system, such as supplying tumor-targeted antibody, activating T cells, enhancing the activity and tumor recognition of NK cells, promoting tumor-targeted phagocytosis of macrophages, and eliminating the immunosuppressive myeloid-derived suppressor cells (MDSCs) and Treg cells. Apart from the immune system, the removal of tumor burden still needs to be assisted by drugs, surgery or radiation. And the body’s internal environment and tumor microenvironment should be improved to recover immune cell function and prevent tumor growth. Multiple microenvironment modulatory therapies may be applied, including addressing hypoxia and oxidative stress, correcting metabolic disorders, and controlling chronic inflammation. Finally, to cure tumor and prevent tumor recurrence, repairing or supporting therapy that consist of tissue repair and nutritional supplement should be applied properly.

show abstract

“…An a-IL-10 antibody administered 24 hours before DC vaccine was able to increase NK responses and was associated with a statistically and clinically significant decrease in tumor growth and increase in survival in a murine breast cancer model. 61 This protocol also made use of a single low dose of cyclophosphamide to decrease regulatory T-cells, but this intervention alone did not result in a change in tumor growth in the absence of the a-IL-10 antibody.…”

Section: Concomitant Immunomodulationmentioning

confidence: 99%

Dendritic cell vaccines: A review of recent developments and their potential pediatric application

Elster

Krishnadas

Lucas

2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

For many cancers the use of conventional chemotherapy has been maximized, and further intensification of chemotherapy generally results in excess toxicity with little long-term benefit for cure. Many tumors become resistant to chemotherapy, making the investigation of novel approaches such as immunotherapy of interest. Because the tumor microenvironment is known to promote immune tolerance and down regulate the body's natural defense mechanisms, modulating the immune system with the use of dendritic cell (DC) therapy is an attractive approach. Thousands of patients with diverse tumor types have been treated with DC vaccines. While antigen specific immune responses have been reported, the duration and magnitude of these responses are typically weak, and objective clinical responses have been limited. DC vaccine generation and administration is a multi-step process with opportunities for improvement in source of DC for vaccine, selection of target antigen, and boosting effector cell response via administration of vaccine adjuvant or concomitant pharmacologic immunomodulation. In this review we will discuss recent developments in each of these areas and highlight elements that could be moved into pediatric clinical trials.

show abstract

Temporary elimination of IL-10 enhanced the effectiveness of cyclophosphamide and BMDC-based therapy by decrease of the suppressor activity of MDSCs and activation of antitumour immune response

Cited by 23 publications

References 32 publications

Immunoregulation of Shenqi Fuzheng Injection Combined with Chemotherapy in Cancer Patients: A Systematic Review and Meta‐Analysis

Immunoregulation of Shenqi Fuzheng Injection Combined with Chemotherapy in Cancer Patients: A Systematic Review and Meta‐Analysis

Novel Therapeutic Strategies for Solid Tumor Based on Body’s Intrinsic Antitumor Immune System

Dendritic cell vaccines: A review of recent developments and their potential pediatric application

Contact Info

Product

Resources

About